P53 Impairs endothelial function by transcriptionally repressing kruppel-Like factor 2

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 1, 2011, Pages 133-141

  Kumar, Ajay ^a   Kim, Cuk Seong ^a   Hoffman, Timothy A ^a   Naqvi, Asma ^a   Dericco, Jeremy ^a   Jung, Saet Byel ^a   Lin, Zhiyong ^b   Jain, Mukesh K ^b   Irani, Kaikobad ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

endothelial function; endothelium; gene expression; NO synthase; thrombosis; vascular biology

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE H3; KRUPPEL LIKE FACTOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; THROMBOMODULIN;

ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ANIMALS; BINDING SITES; BLOOD COAGULATION; CELLS, CULTURED; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROMOTER REGIONS, GENETIC; RATS; RATS, INBRED WKY; RESPONSE ELEMENTS; RNA INTERFERENCE; THROMBOMODULIN; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VASODILATION; VASODILATOR AGENTS;

EID: 78650868271     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.215061     Document Type: Article

References (39)

1. Bieker JJ. Isolation, genomic structure, and expression of human erythroid kruppel-like factor (eklf). DNA Cell Biol. 1996;15:347-352.
2. Kumar A, Lin Z, SenBanerjee S, Jain MK. Tumor necrosis factor alphamediated reduction of klf2 is due to inhibition of mef2 by nf-kappab and histone deacetylases. Mol Cell Biol. 2005;25:5893-5903.
3. Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA Jr, Garcia-Cardena G. Integration of flow-dependent endothelial phenotypes by kruppel-like factor 2. J Clin Invest. 2006;116:49-58.
4. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, Feinberg MW, Chen Z, Simon DI, Luscinskas FW, Michel TM, Gimbrone MA Jr, Garcia-Cardena G, Jain MK. Klf2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004;199:1305-1315.
5. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, Mukherjee P, Mukhopadhyay D, Jain MK. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the kruppel-like factor klf2. J Biol Chem. 2005;280: 28848-28851.
6. Kumar A, Hoffman TA, Dericco J, Naqvi A, Jain MK, Irani K. Transcriptional repression of kruppel like factor-2 by the adaptor protein p66shc. FASEB J. 2009;23:4344-4352.
7. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
8. Ihling C, Haendeler J, Menzel G, Hess RD, Fraedrich G, Schaefer HE, Zeiher AM. Co-expression of p53 and mdm2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol. 1998;185:303-312.
9. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, Serrano M. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002;21:6225-6235.
10. Sanz-Gonzalez SM, Barquin L, Garcia-Cao I, Roque M, Gonzalez JM, Fuster JJ, Castells MT, Flores JM, Serrano M, Andres V. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res. 2007;75: 803-812.
11. Kim CS, Jung SB, Naqvi A, Hoffman TA, DeRicco J, Yamamori T, Cole MP, Jeon BH, Irani K. P53 impairs endothelium-dependent vasomotor function through transcriptional upregulation of p66shc. Circ Res. 2008; 103:1441-1450.
12. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of nf-kappab in p53-mediated programmed cell death. Nature. 2000;404:892-897.
13. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes. 2005;54:1423-1428.
14. Huddleson JP, Ahmad N, Lingrel JB. Up-regulation of the klf2 transcription factor by fluid shear stress requires nucleolin. J Biol Chem. 2006;281:15121-15128.
15. Huddleson JP, Ahmad N, Srinivasan S, Lingrel JB. Induction of klf2 by fluid shear stress requires a novel promoter element activated by a phosphatidylinositol 3-kinase-dependent chromatin-remodeling pathway. J Biol Chem. 2005;280:23371-23379.
16. Sako K, Fukuhara S, Minami T, Hamakubo T, Song H, Kodama T, Fukamizu A, Gutkind JS, Koh GY, Mochizuki N. Angiopoietin-1 induces kruppel-like factor 2 expression through a phosphoinositide 3-kinase/aktdependent activation of myocyte enhancer factor 2. J Biol Chem. 2009; 284:5592-5601.
17. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, Banerjee P, Kumar A, Jain MK. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112:720-726.
18. Yamamori T, White AR, Mattagajasingh I, Khanday FA, Haile A, Qi B, Jeon BH, Bugayenko A, Kasuno K, Berkowitz DE, Irani K. P66shc regulates endothelial no production and endothelium-dependent vasorelaxation: implications for age-associated vascular dysfunction. J Mol Cell Cardiol. 2005;39:992-995.
19. Jeon BH, Gupta G, Park YC, Qi B, Haile A, Khanday FA, Liu YX, Kim JM, Ozaki M, White AR, Berkowitz DE, Irani K. Apurinic/apyrimidinic endonuclease 1 regulates endothelial no production and vascular tone. Circ Res. 2004;95:902-910.
20. Rose SL, Babensee JE. Procoagulant phenotype of endothelial cells after coculture with biomaterial-treated blood cells. J Biomed Mater Res A. 2005;72:269-278.
21. Liu G, Chen X. Regulation of the p53 transcriptional activity. J Cell Biochem. 2006;97:448-458.
22. Grossman SR. P300/cbp/p53 interaction and regulation of the p53 response. Eur J Biochem. 2001;268:2773-2778.
23. Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, Chin MT, Topper JN, Perrella MA, Lee ME. Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via smad3. J Biol Chem. 2000;275:36653-36658.
24. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (hdacs): characterization of the classical hdac family. Biochem J. 2003;370:737-749.
25. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with msin3a. Genes Dev. 1999;13: 2490-2501.
26. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/op18 and fkbp25 genes following p53 induction. Oncogene. 1999;18:5954-5958.
27. Esteve PO, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007;282:2615-2625.
28. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 2003;1: 1515-1524.
29. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 1997; 100:S61-S65. (Pubitemid 28009549)
30. Jin YJ, Wang J, Qiao C, Hei TK, Brandt-Rauf PW, Yin Y. A novel mechanism for p53 to regulate its target gene eck in signaling apoptosis. Mol Cancer Res. 2006;4:769-778.
31. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science. 2002;295:2450-2452.
32. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation of notch1 gene expression by p53 in epithelial cells. Mol Cell Biol. 2007;27:3732-3742.
33. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ. 2003;10:404-408.
34. Ho JS, Ma W, Mao DY, Benchimol S. P53-dependent transcriptional repression of c-myc is required for g1 cell cycle arrest. Mol Cell Biol. 2005;25:7423-7431.
35. Ogden SK, Lee KC, Wernke-Dollries K, Stratton SA, Aronow B, Barton MC. P53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J Biol Chem. 2001;276:42057-42062.
36. Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, Jain MK. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007;282:13769-13779.
37. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:III27-III32.
38. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001;12:383-389.
39. Lee CN, Cheng WF, Chang MC, Su YN, Chen CA, Hsieh FJ. Hypoxiainduced apoptosis in endothelial cells and embryonic stem cells. Apoptosis. 2005;10:887-894.